Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells.

Fiche publication

Date publication

octobre 2022

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DELMAS Dominique , Dr HERMETET François , Dr AIRES Virginie

Tous les auteurs :
Sghaier R, Perus M, Cornebise C, Courtaut F, Scagliarini A, Olmiere C, Aires V, Hermetet F, Delmas D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36233006

Résumé

Age-related macular degeneration (AMD) is an irreversible chronic degenerative pathology that affects the retina. Despite therapeutic advances thanks to the use of anti-vascular endothelial growth factor (VEGF) agents, resistance mechanisms have been found to accentuate the visual deficit. In the present study, we explored whether a nutraceutical formulation composed of omega-3 fatty acids and resveratrol, called Resvega, was able to disrupt VEGF-A secretion in human ARPE-19 retina cells. We found that Resvega inhibits VEGF-A secretion through decreases in both the PI3K-AKT-mTOR and NFκB signaling pathways. In NFκB signaling pathways, Resvega inhibits the phosphorylation of the inhibitor of NFκB, IκB, which can bind NFκB dimers and sequester them in the cytoplasm. Thus, the NFκB subunits cannot migrate to the nucleus where they normally bind and stimulate the transcription of target genes such as VEGF-A. The IκB kinase complex (IKK) is also affected by Resvega since the nutraceutical formulation decreases both IKKα and IKKβ subunits and the IKKγ subunit which is required for the stimulation of IKK. Very interestingly, we highlight that Resvega could prolong the anti-angiogenic effect of Avastin, which is an anti-VEGF agent typically used in clinical practice. Our results suggest that Resvega may have potential interest as nutritional supplementation against AMD.